Why Zepbound (tirzepatide) Causes Diarrhea: The Mechanism Explained

By
Published Updated Last reviewed
Medication safety clinical consultation image for Why Zepbound (tirzepatide) Causes Diarrhea: The Mechanism Explained

Why Zepbound (Tirzepatide) Causes Diarrhea: The Mechanism Explained

At a glance

  • Incidence in trials: 12.6% to 16.8% across the 5 mg, 10 mg, and 15 mg doses in the SURMOUNT-1 trial, compared with 4.8% on placebo
  • Typical timeline: Most episodes begin within the first 4 to 8 weeks of treatment, particularly during dose-escalation phases (FDA Zepbound prescribing information)
  • First-line management: Dietary modification (smaller meals, reduced fat intake), adequate hydration, and temporary use of loperamide if needed (AGA clinical guidance on GLP-1 RA GI effects, 2024)
  • When to escalate: Diarrhea persisting beyond 72 hours with signs of dehydration, electrolyte abnormalities, or inability to maintain oral intake
  • When to consider discontinuation: Severe or refractory diarrhea unresponsive to dose reduction and supportive measures, or concurrent pancreatitis symptoms

Dual-Incretin Signaling: Why Two Receptors Matter for the Gut

Tirzepatide is not a standard GLP-1 receptor agonist. It is a dual GIP/GLP-1 receptor agonist, meaning it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. This dual mechanism is central to understanding why its GI side-effect profile differs from pure GLP-1 RAs like semaglutide.

GLP-1 receptors are expressed throughout the enteric nervous system, on vagal afferent neurons, and on intestinal epithelial cells (Drucker DJ. Cell Metab. 2018). When tirzepatide binds these receptors, it triggers signaling cascades that slow gastric emptying, reduce antral contractions, and alter the migrating motor complex (the "housekeeper" wave that moves content through the small bowel between meals). GIP receptors, found on enteroendocrine K-cells and in duodenal and jejunal mucosa, add a second layer of signaling that modulates intestinal secretion and mucosal blood flow (Campbell JE, Drucker DJ. Cell Metab. 2013).

The result is a gut receiving conflicting signals. Gastric emptying slows (food stays in the stomach longer), yet downstream segments of the small intestine increase their secretory output. This mismatch is a primary driver of the osmotic and secretory diarrhea that patients experience.

How Altered Motility Produces Loose Stools

Tirzepatide's effect on gut motility is dose-dependent and biphasic. Data from the SURMOUNT-1 and SURMOUNT-2 trials show that GI adverse events cluster around dose-escalation windows. This pattern reflects a period when receptor stimulation outpaces the gut's ability to adapt.

At the smooth-muscle level, GLP-1 receptor activation inhibits acetylcholine release from myenteric neurons. This reduces the frequency and amplitude of peristaltic contractions in the stomach and proximal small bowel (Halim MA et al. Diabetes Obes Metab. 2019). While this slows transit proximally, it creates a "traffic jam" effect. Chyme that eventually passes the pylorus arrives in larger, less-processed boluses into the jejunum and ileum.

These larger boluses overwhelm the absorptive capacity of the distal small intestine. Water and electrolytes that would normally be absorbed during slower, steadier transit instead pass into the colon. The colon has a finite capacity to reclaim fluid (approximately 1.5 to 2 liters per day in healthy adults). When that threshold is exceeded, the result is loose or watery stools (Schiller LR. Gastroenterol Clin North Am. 2017).

Tirzepatide also appears to increase chloride-channel activity on enterocytes via cAMP-dependent pathways. GLP-1 receptor signaling raises intracellular cAMP, which activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. Chloride secretion into the intestinal lumen draws sodium and water along osmotically (Barrett KE, Keely SJ. Annu Rev Physiol. 2000). This active secretory component explains why some patients experience watery diarrhea even on stable doses.

The Bile-Acid Hypothesis

A growing body of evidence points to bile-acid malabsorption (BAM) as a contributing mechanism. Under normal physiology, roughly 95% of bile acids are reabsorbed in the terminal ileum via the apical sodium-dependent bile acid transporter (ASBT). The remaining 5% spill into the colon, where they are tolerated without symptoms.

GLP-1 receptor activation accelerates gallbladder refilling and may alter the timing of bile-acid release relative to meal transit (Smits MM et al. Diabetes Obes Metab. 2016). If bile acids arrive in the ileum before adequate absorptive contact time (because of the motility mismatch described above), more bile acids escape into the colon.

Colonic bile acids, particularly dihydroxy bile acids like chenodeoxycholic acid, are potent secretagogues. They activate the TGR5 receptor on colonocytes and stimulate chloride and water secretion (Mekjian HS et al. J Clin Invest. 1971). They also increase colonic motility by stimulating serotonin release from enterochromaffin cells. The clinical picture this produces (urgency, watery stools, often worse after fatty meals) overlaps heavily with the diarrhea pattern that Zepbound patients describe.

This bile-acid mechanism has been documented more formally in the broader GLP-1 RA class. A 2023 analysis in Alimentary Pharmacology & Therapeutics found that patients on GLP-1 RAs had elevated serum C4 levels (a marker of bile-acid synthesis) and higher fecal bile-acid concentrations compared to matched controls (Xiao R et al. Aliment Pharmacol Ther. 2023). While this study examined liraglutide and semaglutide specifically, the shared GLP-1 receptor pharmacology makes the finding directly relevant to tirzepatide.

Why Diarrhea Is Worse During Dose Escalation

The Zepbound prescribing information recommends a slow titration schedule: 2.5 mg for 4 weeks, then 5 mg, then 7.5 mg, and so on. This schedule exists specifically because the enteric nervous system needs time to downregulate receptor sensitivity.

During each dose increase, peak plasma concentrations of tirzepatide rise, and GLP-1/GIP receptor occupancy in the gut increases accordingly. Tachyphylaxis (receptor desensitization) develops over 2 to 4 weeks at each dose level, which is why most patients find that diarrhea improves without intervention if they hold their dose steady (Jastreboff AM et al. N Engl J Med. 2022). Patients who escalate faster than recommended, or who are unusually sensitive to incretin signaling, are at higher risk for persistent GI symptoms.

Practical Implications for Management

Understanding the mechanism guides management. Because the diarrhea has both a motility component and a secretory component, treatment that addresses only one pathway may be insufficient.

Dietary strategies target the motility mismatch. Smaller, lower-fat meals reduce the volume of chyme delivered per bolus and limit bile-acid release. Soluble fiber (psyllium, oat-based) adds bulk and slows colonic transit without worsening secretion (AGA clinical guidance, 2024).

Loperamide addresses the motility component by activating mu-opioid receptors in the myenteric plexus, slowing colonic transit and increasing fluid absorption. It does not address the secretory component. For patients with a predominantly secretory pattern (high-volume watery stools), a bile-acid sequestrant like cholestyramine may be more effective (Walters JRF. Therap Adv Gastroenterol. 2015).

Dose management remains the most effective intervention. Holding at the current dose for an additional 4 weeks before escalating allows enteric receptor desensitization to catch up. In the SURMOUNT trials, the majority of diarrhea episodes were mild to moderate and resolved without treatment discontinuation (Jastreboff AM et al. N Engl J Med. 2022).

Frequently asked questions

›
›
›
›
›
›
›
›
›
›

References